Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
- PMID: 11547741
- DOI: 10.1056/NEJMoa010187
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
Abstract
Background: Surgical resection of adenocarcinoma of the stomach is curative in less than 40 percent of cases. We investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction.
Methods: A total of 556 patients with resected adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to surgery plus postoperative chemoradiotherapy or surgery alone. The adjuvant treatment consisted of 425 mg of fluorouracil per square meter of body-surface area per day, plus 20 mg of leucovorin per square meter per day, for five days, followed by 4500 cGy of radiation at 180 cGy per day, given five days per week for five weeks, with modified doses of fluorouracil and leucovorin on the first four and the last three days of radiotherapy. One month after the completion of radiotherapy, two five-day cycles of fluorouracil (425 mg per square meter per day) plus leucovorin (20 mg per square meter per day) were given one month apart.
Results: The median overall survival in the surgery-only group was 27 months, as compared with 36 months in the chemoradiotherapy group; the hazard ratio for death was 1.35 (95 percent confidence interval, 1.09 to 1.66; P=0.005). The hazard ratio for relapse was 1.52 (95 percent confidence interval, 1.23 to 1.86; P<0.001). Three patients (1 percent) died from toxic effects of the chemoradiotherapy; grade 3 toxic effects occurred in 41 percent of the patients in the chemoradiotherapy group, and grade 4 toxic effects occurred in 32 percent.
Conclusions: Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection.
Comment in
-
Adjuvant chemoradiotherapy for gastric cancer.N Engl J Med. 2002 Jan 17;346(3):210-1. doi: 10.1056/NEJM200201173460316. N Engl J Med. 2002. PMID: 11796861 No abstract available.
-
Adjuvant chemoradiotherapy for gastric cancer.N Engl J Med. 2002 Jan 17;346(3):210-1. N Engl J Med. 2002. PMID: 11797725 No abstract available.
-
Adjuvant chemoradiotherapy for gastric cancer.N Engl J Med. 2002 Jan 17;346(3):210-1. N Engl J Med. 2002. PMID: 11797726 No abstract available.
-
Does chemoradiotherapy after intended curative surgery increase survival of gastric cancer patients?Gut. 2002 Jun;50(6):751. doi: 10.1136/gut.50.6.751. Gut. 2002. PMID: 12010873 Free PMC article. No abstract available.
-
Chemotherapy for pancreatic cancer.N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5. N Engl J Med. 2004. PMID: 15218575 No abstract available.
-
Treatment of gastric cancer.N Engl J Med. 2006 Sep 28;355(13):1387; author reply 1387-8. N Engl J Med. 2006. PMID: 17014037 No abstract available.
Similar articles
-
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85. doi: 10.1016/j.ijrobp.2005.05.005. Epub 2005 Aug 15. Int J Radiat Oncol Biol Phys. 2005. PMID: 16099596
-
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med. 2006 Jul 6;355(1):11-20. doi: 10.1056/NEJMoa055531. N Engl J Med. 2006. PMID: 16822992 Clinical Trial.
-
Postoperative chemoradiotherapy for gastric cancer.Ann Oncol. 2003 Sep;14(9):1373-7. doi: 10.1093/annonc/mdg366. Ann Oncol. 2003. PMID: 12954575 Clinical Trial.
-
Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.Cochrane Database Syst Rev. 2013 May 31;(5):CD008107. doi: 10.1002/14651858.CD008107.pub2. Cochrane Database Syst Rev. 2013. PMID: 23728671 Review.
-
Role of post-operative chemoradiation in resected gastric cancer.J Surg Oncol. 2005 Jun 1;90(3):166-70. doi: 10.1002/jso.20223. J Surg Oncol. 2005. PMID: 15895449 Review.
Cited by
-
Preoperative chemoradiotherapy for locally advanced gastric cancer.Radiat Oncol. 2013 Jan 4;8:6. doi: 10.1186/1748-717X-8-6. Radiat Oncol. 2013. PMID: 23286735 Free PMC article.
-
Intraoperative Assessment and Photothermal Ablation of the Tumor Margins Using Gold Nanoparticles.Adv Sci (Weinh). 2021 Jan 18;8(5):2002788. doi: 10.1002/advs.202002788. eCollection 2021 Mar. Adv Sci (Weinh). 2021. PMID: 33717843 Free PMC article.
-
Histone demethylase Jumonji domain-containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt-related transcription factor 3.Cancer Sci. 2020 Oct;111(10):3679-3692. doi: 10.1111/cas.14594. Epub 2020 Sep 6. Cancer Sci. 2020. PMID: 32762126 Free PMC article.
-
Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia.Radiol Oncol. 2012 Dec;46(4):337-45. doi: 10.2478/v10019-012-0049-4. Epub 2012 Nov 9. Radiol Oncol. 2012. PMID: 23412351 Free PMC article.
-
Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy.Front Pharmacol. 2020 Jun 30;11:960. doi: 10.3389/fphar.2020.00960. eCollection 2020. Front Pharmacol. 2020. PMID: 32694998 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical